Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, John Rose, Jack H. Simon et al.|The Lancet Neurology|2010Cited by 300
MS disease activity in RESTORERobert J. Fox, Petra W. Duda, Bruce Cree et al.|Neurology|2014Cited by 192